NASDAQ: PODD

Insulet (PODD) Stock Analysis & Forecast

Nov 13 close

$152.48+3.19 (+2.1%)

Gekko Brief

Nov 9 close

Insulet closed at $149.81 on 9 November 2026, +2.3% on the day. The price sits between the 50-day ($142.06) and 200-day ($174.95) moving averages, inside a 52-week range of $126.40 to $354.88. The GekkoIndex reads 56.3, in the Neutral zone, up 9.5 points over five sessions. Gekko Fair Value is $152.05, so the price is 1.5% below it.

The next earnings report is due on 17 February 2027, 94 days away. Over the last 8 reports the company beat the earnings estimate 8 times, with an average move of 6.6% across the report. Smart-money activity over the last 90 days includes 1 open-market insider purchase and 2 Congress purchases and 0 sales. Over the last 30 days there were 2 unusual options signals. Seasonally, the next 20 trading days from this point averaged +1.4% over the last 5 years, rising in 2 of them.

14 firms rate the stock: 6 buy, 8 hold and 0 sell, with a consensus target of $167.17. A typical daily move is about 4.8%, and a typical 20-day move about 7%. On the swing-trade checklist, 2 items read supportive and 0 read as a headwind.

A plain summary of the figures as of the Nov 9, 2026 close.

Insulet price vs fair value

$156.71$152.48Nov ’25May ’26Nov ’26
Close $152.48200-day averageGekko Fair Value $156.71

Insulet quick facts

Market cap
$10.58B
P/E ratio
24.5
Forward P/E
19.4
EPS, TTM
$6.09
Revenue, TTM
$3.19B
Profit margin
13.4%
Dividend yield
—
Beta
1.05
Volume
1.18M avg 1.31M
1-year return
−54.7%
Typical daily move
±4.6%
Typical 20-day move
±7%
50-day average
$142.14
200-day average
$172.70
Next earnings
Feb 17
Shares outstanding
69.37M
52-week range
$126.40$354.88

Insulet swing-trade checklist

Insulet scores 2 supportive, 4 mixed and 0 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

2 supportive4 mixed0 headwinds

  • Trendmixed

    Averages disagree

    Close $152.48 sits between the 50-day ($142.14) and 200-day ($172.70) averages, or the averages disagree.

    See the chart
  • GekkoIndexmixed

    57, Neutral

    Reading 57 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuemixed

    2.7% below

    Price is within 5% of Gekko Fair Value (2.7% below).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 90 days: 1 open-market insider purchase; Congress 2 buys / 0 sales. Last 30 days: 2 unusual options signals.

    See smart money
  • Earnings risksupportive

    Reports in 94 days

    Next report Feb 17, 2027, 94 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitymixed

    −0.9% on average

    From this point in the calendar, the next 20 trading days averaged −0.9% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Insulet stock chart and price history

Insulet closed at $152.48 on Nov 13, 2026, −54.7% over the past year, inside a 52-week range of $126.40 to $354.88.

Close50-day average200-day averageVolume
Insulet share price, past year, with 50-day and 200-day moving averages and volume$200$250$300$350DecJan 2026FebMarAprMayJunJulAugSepOctNov152.48

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+9.9%
3 months
+9.1%
6 months
+3.4%
1 year
−54.7%
The full PODD chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open PODD in Gekko

Follow Insulet through every session

Put PODD on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track PODD in GekkoFree for 7 days. No credit card required.

About Insulet

Insulet designs and produces wearable insulin delivery devices for people who require insulin therapy, serving patients across the United States and other countries. Its Omnipod line is the centerpiece of the business, spanning the Omnipod 5 automated system that pairs a pod-embedded algorithm with a third-party continuous glucose monitor over Bluetooth, the Omnipod DASH system operated through a touchscreen personal diabetes manager, and the original Omnipod Insulin Management System.

Beyond diabetes care, the company manufactures pods used by Amgen in the Neulasta Onpro kit, a delivery mechanism intended to lower infection risk following intensive chemotherapy. Insulet reaches patients through pharmacy channels as well as a network of independent distributors, combining direct retail access with third-party distribution.

The company was incorporated in 2000 and is based in Acton, Massachusetts. Its shares trade on the NASDAQ under the ticker PODD.

Listed
NASDAQ
Sector
Health technology
Industry
Medical specialties
Website
insulet.com

Insulet GekkoIndex: the smart money zone

Insulet’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 57, in the Neutral zone, up 2 points over five sessions.

010057Neutral

Up 2 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying36−1.0%−1.7%−7.9%−12.9%
Accumulation293−0.1%−0.7%0.0%−2.1%
Neutral (current zone)338+0.1%+0.6%+0.5%+2.3%
Distribution28+0.3%−0.8%−2.7%+1.3%
Selling7Too few readings yet

Average PODD share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the PODD price, zone by zone.Track PODD in Gekko

Is Insulet stock overvalued? Gekko Fair Value

Insulet trades 2.7% below Gekko Fair Value of $156.71, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what Insulet shares are worth, recalculated every trading day.

$156.71

Gekko Fair Value, Nov 14, 2026

2.7% below fair value · About fair value

At the end of Aug 2026 the price was 10.3% below the estimate.

Gekko Fair ValueShare price, month end
$157$152Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open PODD in Gekko

Insulet insider and Congress trading

Insiders filed 1 open-market purchase in Insulet worth $162K, and members of Congress disclosed 2 purchases and 0 sales, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

$162Kin 1 open-market purchase

FiledInsiderTypeSharesValue
Aug 24McEvoy Ashley
director, officer: President and CEO
Purchase1,100$162K

From Form 4 filings, dated to when each was filed.

Congress trades last 90 days

2trades disclosed: 2 purchases and 0 sales.

MemberTypeAmountDisclosed
Ro Khanna
House, CA, purchase
Purchase$1,001 - $15,000Oct 9
traded Sep 11
Gilbert Cisneros
House, CA, purchase
Purchase$1,001 - $15,000Sep 11
traded Aug 18

From congressional disclosures, which report amounts as ranges.

Buybacks

Insulet has been buying back its own shares.

Latest authorization
$1.00B, Nov 4, 2026
Bought back, quarter ended Jun 30, 2026
$300.0M
As a share of market cap
2.84%

From company filings.

Unusual options activity last 30 days

2signals, 70% of the flagged premium in calls.

Latest: Bearish flow on Nov 4, $772K in unusual premium.

Hedge funds and billionaires quarter ended Jun 30

1of the funds Gekko tracks holds PODD.

0added1opened0trimmed0sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

Insulet earnings: next date and track record

Insulet reports on Feb 17, 2027 (94 days away), and beat the EPS estimate in 8 of its last 8 reports.

8 of 8reports beat the EPS estimate
±6.6%average move across the report
5 of 8reports followed by a gain

Share-price move across each report

−0.3%Feb ’25+17.5%May ’25+10.7%Aug ’25+1.7%Nov ’25+1.1%Feb ’26−4.3%May ’26−16.5%Aug ’26+0.8%Nov ’26

Last earnings call, Nov 4, 2026 AI summary

What they said
Insulet reported Q3 2026 revenue of $842 million, up ~20% YoY with ~15% US growth and 33% international growth. Global customer base grew 20%+ YoY, surpassing 600K customers. Record gross margin and expanded operating margin were achieved. Type 2 diabetes patients account for over 40% of US new starts, with no observed GLP-1 headwind. Management narrowed full-year guidance to the top end of prior range.
Guidance
Full-year 2026 revenue guidance narrowed to the top end of prior range. For 2027, management expects accelerating innovation including Omnipod 6 launch and a more dynamic competitive environment, anticipating continued category growth.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 4, 2026$1.99
est $1.59
+25.2%$842.0M
est $832.6M
+1.1%+0.8%
Aug 5, 2026$1.66
est $1.47
+12.9%$801.7M
est $787.4M
+1.8%−16.5%
May 6, 2026$1.42
est $1.19
+19.3%$761.7M
est $729.9M
+4.4%−4.3%
Feb 18, 2026$1.55
est $1.47
+5.4%$783.8M
est $769.0M
+1.9%+1.1%
Nov 6, 2025$1.24
est $1.14
+8.8%$706.3M
est $678.4M
+4.1%+1.7%
Aug 7, 2025$1.17
est $0.92
+27.2%$649.1M
est $614.2M
+5.7%+10.7%
May 8, 2025$1.02
est $0.79
+29.1%$569.0M
est $543.3M
+4.7%+17.5%
Feb 20, 2025$1.15
est $1.00
+15.0%$597.5M
est $582.5M
+2.6%−0.3%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Insulet stock forecast and analyst price targets

Analysts’ average 12-month price target for Insulet is $178.57, +17.1% from the last close, from 14 firms rating the stock in the last 90 days.

$178.57consensus 12-month target, +17.1% from the last close
Low $160High $200
Buy6
Hold8
Sell0

Each firm’s latest rating in the last 90 days: 14 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 9Truist FinancialHold, maintained$160+4.9%
Nov 6BarclaysHold, maintained$165+8.2%
Nov 5Stifel NicolausBuy, maintained$180+18.0%
Nov 5BernsteinBuy, reiterated$200+31.2%
Nov 5CitiHold, maintained$170+11.5%
+0.5%average 20-day move after past Neutral readings
−0.9%average move over the next 20 trading days in the last 5 years
±4.6%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Insulet seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Insulet averaged −0.9% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−19.3%2021+7.9%2022+18.4%2023+3.1%2024−12.4%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−0.4%2 of 5
Next 10 trading days−1.5%1 of 5
Next 15 trading days−2.5%2 of 5
Next 20 trading days−0.9%3 of 5
Next 30 trading days−0.6%1 of 5

For scale, PODD’s typical 20-trading-day move in either direction is about 7%.

Insulet market cap and key statistics

Insulet’s market cap is $10.58B, with a P/E ratio of 24.5 and revenue of $3.19B over the last twelve months.

Valuation

Market cap
$10.58B
P/E ratio
24.5
Forward P/E
19.4
EPS, TTM
$6.09
Gekko Fair Value
$156.71

Trading

Volume
1.18M
Avg volume, 20 days
1.31M
52-week high
$354.88
52-week low
$126.40
Shares outstanding
69.37M

Financials

Revenue, TTM
$3.19B
Profit margin
13.4%
Return on equity
28.9%
Quarterly earnings growth, YoY
+63.7%

Risk and income

Beta
1.05
Typical daily move
±4.6%
Typical 20-day move
±7%

Insulet stock news this week

Coverage of Insulet this week reads positive: 6 positive, 2 neutral and 0 negative headlines.

News sentiment positive

Insulet peers

Insulet’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
TMOThermo Fisher Scientific−0.2%Neutral15.0% above
ABTAbbott Laboratories+0.3%Neutral10.5% below
DHRDanaher0.0%Neutral4.7% above
ISRGIntuitive Surgical0.0%Neutral17.5% above
MDTMedtronic+0.7%Neutral14.2% below
SYKStryker−2.0%Neutral0.1% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical specialties

Insulet stock FAQ

What is Insulet’s market cap?

Insulet’s market cap is $10.58B at the Nov 13, 2026 close of $152.48, with 69.37M shares outstanding. The shares trade on a P/E ratio of 24.5.

What is the Insulet stock forecast?

The consensus analyst 12-month price target for Insulet is $178.57, +17.1% from the last close. Of the 14 firms that rated the stock in the last 90 days, 6 rate it a buy, 8 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Insulet stock overvalued or undervalued?

On Gekko’s estimate Insulet is about fair value: the Nov 13, 2026 close of $152.48 is 2.7% below Gekko Fair Value of $156.71. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Insulet report earnings next?

Insulet is expected to report on Feb 17, 2027 (94 days away). Analysts expect earnings of $1.74 per share on revenue of $899.8M. Insulet beat the earnings estimate in 8 of its last 8 reports, moving 6.6% on average across the report.

What is Insulet’s 52-week high and low?

Insulet’s 52-week high is $354.88 and its 52-week low is $126.40; it closed at $152.48 on Nov 13, 2026, −54.7% over the past year.

Is Insulet stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 6 items with data read as supportive (smart money and earnings risk), 4 as mixed (trend, gekkoindex, fair value and seasonality). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in Insulet?

Gekko flagged 2 unusual options signals in Insulet over the last 30 days, with $1.51M of flagged premium in calls and $649K in puts. The latest, bearish flow, was on Nov 4, 2026 with $772K in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Insulet the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.